Drug Details

General Information of the Drug (ID: DR1112)
Name
Nitazoxanide
Synonyms
NITAZOXANIDE; 55981-09-4; Alinia; Nitazoxamide; 2-((5-nitrothiazol-2-yl)carbamoyl)phenyl acetate; Daxon; Nitazoxanidum [INN-Latin]; Nitazoxanida [INN-Spanish]; Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)-; 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate; 2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide; C12H9N3O5S; [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate; UNII-SOA12P041N; NTZ; NSC697855; 2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide; Nitazoxanide (Alinia, Annita); SOA12P041N; Nitazoxanida; Nitazoxanide-d4; 2-(Acetyloxy)-N-(5-nitro-2-thiazolyl)benzamide; MFCD00416599; NSC-697855; PH 5776; PH-5776; NCGC00090774-01; Nitazoxanid; Nitazoxanidum; Colufase; Cryptaz; Heliton; DSSTox_CID_13757; DSSTox_RID_79095; DSSTox_GSID_33757; Phavic-1; acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester; SMR000466367; NSC 697855; Alinia (TN); AZT + Nitazoxanide; CAS-55981-09-4; 1246819-17-9; EINECS 259-931-8; Nitazoxanide (USAN/INN); (2-((5-Nitro-2-thiazolyl)carbamoyl)phenyl)acetat; BRN 1225475; N-(5-Nitro-2-thiazolyl)salicylamide acetate (ester); Nitrazoxanide; Pacovanton; Dexidex; Kidonax; Nitazox; Paramix; Nitax; Toza; Nitazoxanide [USAN:INN:BAN]; Alinia(TM); N-(5-Nitrothiazol-2-yl)salicylamide acetate ester; o-(N-(5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate; Salicylamide, N-(5-nitro-2-thiazolyl)-, acetate (ester); CPD000466367; NCIMech_000843; CHEMBL1401; Oprea1_263587; SCHEMBL40981; MLS000759492; MLS001424074; MLS006010127; [2-[(5-nitrothiazol-2-yl)carbamoyl]phenyl] acetate; DTXSID5033757; CHEBI:94807; Nitazoxanide, >=98% (HPLC); NTZ;NSC 697855; HMS2051L04; HMS3393L04; HMS3655M11; HMS3715F10; Pharmakon1600-01503843; BCP13918; HY-B0217; ZINC3956788; Tox21_111018; Tox21_201226; BDBM50075050; CCG-35851; CN0040; MMV688991; NSC760057; STK395664; AKOS015915393; Tox21_111018_1; AC-1302; DB00507; KS-1160; MCULE-8701444531; NC00246; NSC-760057; NCGC00090774-02; NCGC00090774-03; NCGC00090774-04; NCGC00090774-05; NCGC00258778-01; AK-26130; NCI60_034935; AB0010620; FT-0601547; N1031; Nitrazoxanide 100 microg/mL in Acetonitrile; S1627; ST51059722; SW197626-2; 2-(5-nitrothiazol-2-ylcarbamoyl)phenyl acetate; D02486; J10428; S-3645; AB00639988-07; AB00639988-09; AB00639988_10; AB00639988_11; 981N094; A830877; Q-201475; Q2943789; NTZ; 2-(Acetyloxy)-N-(5-nitro-2-thiazolyl)benzamide; Salicylamide, N-(5-nitro-2-thiazolyl)- acetate (ester); Z1514087129; 2-[N-(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate; [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] ethanoate; Nitazoxanide, United States Pharmacopeia (USP) Reference Standard; [2,3,4,5-tetradeuterio-6-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate; Zox
    Click to Show/Hide
Molecular Type
Small molecule
Disease Diarrhea [ICD-11: ME05] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C12H9N3O5S
PubChem CID
41684
Canonical SMILES
CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-]
InChI
1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)
InChIKey
YQNQNVDNTFHQSW-UHFFFAOYSA-N
CAS Number
CAS 55981-09-4
ChEBI ID
CHEBI:94807
TTD Drug ID
D08EBN
DrugBank ID
DB00507
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Spiramycin      Streptomyces ambofaciens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model 6-8 weeks old Swiss strain albino mice were used in this study.
                    Experimental
                    Result(s)		 SP-metronidazole gave the foremost effect on both mice survival rate and parasite load in the liver, spleen and brain.
Target and Pathway
Target(s) Cryptosporidium Pyruvate dehydrogenase (Crypto CpPNO)  Molecule Info  [3]
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021497.
Reference 2 Effect of nitazoxanide and spiramycin metronidazole combination in acute experimental toxoplasmosis. Heliyon. 2020 Apr 16;6(4):e03661.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link